The previously reported primary endpoint results of the trial had shown that the addition of apalutamide to ADT significantly improved both radiographic progression-free survival and overall survival.
In a related commentary, authors state these results suggest apalutamide is well tolerated in these patients, and therefore it seems to be a favourable option for patients from the points of view of both survival and quality of life. However, as noted by authors of this editorial, other relevant patient outcomes, such as mood disturbance, insomnia, and cognitive deficits, were not assessed, meaning that the evaluation of quality of life was not extensive.